The United States has formally accepted an amendment to the World Trade Organization’s agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) that allows developing countries to import generic versions of patented anti-HIV medications, ending years of U.S. opposition to such imports. The amendment allows countries without the capacity for making such generic drugs to import them from countries that can manufacture them. Two thirds of the WTO members must approve the amendment before December 1, 2007, for it to become a permanent part of the TRIPS agreement. U.S. trade representative Rob Portman says the United States was the first country to formally approve it. "Our acceptance of this amendment is an important step in the global effort in providing the best access to lifesaving drugs,” Portman told London's AFX News. (Advocate.com)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.